January 4, 2010
Posted by on
As we head into another budget cycle here in Ontario, there has been a flood of news showing that other jurisdictions are investing heavily in recruitment and stimulus for biotech companies. Each one of these investments raises the bar for what has to be done in Ontario to build our own companies and capitalize effectively on our R&D resource base:
- Close to home, Quebec’s recently-announced $122 million Biopharmaceutical Strategy is expected to match Ontario’s OTEC tax holiday (not so useful for biotech) and adds $30 million for R&D credit monetization (fantastically useful for biotech).
- Across the border in the U.S., things have been even busier. The Senate version of the health care reform bill includes the famous (/infamous) 12-year exclusivity period for biologics, but according to a BioWorld article the bill also includes “a therapeutic discovery project tax credit.” Sen. Arlen Specter (D-Pa.) also reportedly offered a measure that would create a translational science grant program through the National Institutes of Health, called the Cures Acceleration Network, and that would aid in expediting the FDA review.
- Add to the federal stimulus an array of state-level initiatives:
- Even the traditional U.S. biotech hotbeds are not standing still: North Carolina’s $250 million innovation fund is almost up and running, with an RFP out for a fund manager. (h/t @GenomicsLawyer)
- And in case you still think we can afford to rest on the laurels of the OETF and OVCF, take a look at John McCulloch’s post on the MaRS blog about his trip to the Suzhou New District in China, which has already incubated NASDAQ-listed solar power company Canadian Solar.
Image from User:Bdk on WikiMedia under the GNU Free Documentation License.
April 13, 2009
Posted by on
New data from Delaware and Arizona last week:
Some highlights from a study by Edward Ratledge and Simon Condliffe of the University of Delaware’s Center for Applied Demography and Survey Research:
- The biopharmaceuticals industry contributed $4 billion to Delaware’s economic output in 2008.
- 247 biopharmaceutical firms employing 12,000 people, paying $1.6 billion in wages,
- average salary of $132,000, which grew at a pace of 22.8% over the past five years, almost 8% faster than the wages of Delaware’s other industries
- An additional 16,000 people are employed in support industries.
- The industry is expected to add more than 120,000 jobs nationwide between now and 2016.
In Arizona, a similar study by Battelle Technology Partnership Practice had the following stats:
- The state of Arizona and private philanthropists have pledged more than $1 billion to grow Arizona’s bioscience economy.
- Excluding biotech jobs at hospitals and university labs, the industry employed 13,543 workers who earned $777.8 million [= average salary of $57,432] and contributed $177.8 million in state and local taxes.
For more stats on life sciences money and jobs, see our Bailout Page.